Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Susanna Bormioli, Andrea Matucci, Laura Dies, Francesca Nencini, Francesca Grosso, Enrico Maggi, Alessandra Vultaggio

ABSTRACT

Background: Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term side effects with conventional treatment options can be a significant clinical problem. Recently, novel therapeutic approaches focus on targeting skewed immune responses providing a more effective, and less harmful approach. Among them, variable success has been reported using Omalizumab, when used in combination with classic therapies. This report describes an interesting case of severe adult onset difficult-to-treat atopic dermatitis dramatically improved in response to treatment with Omalizumab. Case presentation: We present a case of an adult male with severe allergic atopic dermatitis, with concomitant involvement of the face, neckline, trunk and forearms and systemic symptoms such as diarrhoea with important decrease of his daily quality of life. The patient had been prescribed oral steroids in addition to anti-histamines to no avail. Due to lack of response to classic therapies, strict diet, as well as to treatment with intravenous corticosteroids, an off-label treatment with Omalizumab based on patient weight and total IgE value was proposed. Clear clinical results were observed after only a few weeks with regards to systemic symptoms, and just after 2 months of treatment in regards to skin involvement. Conclusions: In the majority of treated patients the clinical improvement of cutaneous manifestations is expected after several months of treatment, as skin manifestations are the consequence of a chronic inflammatory process. The outstanding rapid response observed in this case as well as the persistence of the clinical remission suggests that the block of the IgE pathways modulate functions of cells involved in the pathogenic mechanisms of chronic skin inflammation but also in the acute phases observed in the flare-ups of the disease. More... »

PAGES

5

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12948-019-0109-z

DOI

http://dx.doi.org/10.1186/s12948-019-0109-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112689654

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30911288


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Immunology and Cellular Therapy, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bormioli", 
        "givenName": "Susanna", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Immunoallergology Unit, Department of Biomedicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matucci", 
        "givenName": "Andrea", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Immunology and Cellular Therapy, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dies", 
        "givenName": "Laura", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Immunoallergology Unit, Department of Biomedicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nencini", 
        "givenName": "Francesca", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Immunology and Cellular Therapy, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grosso", 
        "givenName": "Francesca", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Immunology and Cellular Therapy, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maggi", 
        "givenName": "Enrico", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliero-Universitaria Careggi", 
          "id": "https://www.grid.ac/institutes/grid.24704.35", 
          "name": [
            "Immunoallergology Unit, Department of Biomedicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vultaggio", 
        "givenName": "Alessandra", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)00149-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003359813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/all.13083", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015924470"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaci.2009.10.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033887469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.200312-1651oc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037944429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaci.2016.05.038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048996340"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2016/8163803", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053444706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s41232-017-0044-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085865564", 
          "https://doi.org/10.1186/s41232-017-0044-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s41232-017-0044-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085865564", 
          "https://doi.org/10.1186/s41232-017-0044-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "Background: Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term side effects with conventional treatment options can be a significant clinical problem. Recently, novel therapeutic approaches focus on targeting skewed immune responses providing a more effective, and less harmful approach. Among them, variable success has been reported using Omalizumab, when used in combination with classic therapies. This report describes an interesting case of severe adult onset difficult-to-treat atopic dermatitis dramatically improved in response to treatment with Omalizumab.\nCase presentation: We present a case of an adult male with severe allergic atopic dermatitis, with concomitant involvement of the face, neckline, trunk and forearms and systemic symptoms such as diarrhoea with important decrease of his daily quality of life. The patient had been prescribed oral steroids in addition to anti-histamines to no avail. Due to lack of response to classic therapies, strict diet, as well as to treatment with intravenous corticosteroids, an off-label treatment with Omalizumab based on patient weight and total IgE value was proposed. Clear clinical results were observed after only a few weeks with regards to systemic symptoms, and just after 2\u00a0months of treatment in regards to skin involvement.\nConclusions: In the majority of treated patients the clinical improvement of cutaneous manifestations is expected after several months of treatment, as skin manifestations are the consequence of a chronic inflammatory process. The outstanding rapid response observed in this case as well as the persistence of the clinical remission suggests that the block of the IgE pathways modulate functions of cells involved in the pathogenic mechanisms of chronic skin inflammation but also in the acute phases observed in the flare-ups of the disease.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12948-019-0109-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031275", 
        "issn": [
          "1476-7961"
        ], 
        "name": "Clinical and Molecular Allergy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient", 
    "pagination": "5", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2ae1ea4f610a2588750ff24aef603a48a8b8859a146070bed6b1ad5378d4cf9d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30911288"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101152195"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12948-019-0109-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112689654"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12948-019-0109-z", 
      "https://app.dimensions.ai/details/publication/pub.1112689654"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130797_00000006.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12948-019-0109-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12948-019-0109-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12948-019-0109-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12948-019-0109-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12948-019-0109-z'


 

This table displays all metadata directly associated to this object as RDF triples.

126 TRIPLES      21 PREDICATES      36 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12948-019-0109-z schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N60aa0cbd8ef146008d5e57899290bc5b
4 schema:citation sg:pub.10.1186/s41232-017-0044-7
5 https://doi.org/10.1016/j.jaci.2009.10.021
6 https://doi.org/10.1016/j.jaci.2016.05.038
7 https://doi.org/10.1016/s0140-6736(15)00149-x
8 https://doi.org/10.1111/all.13083
9 https://doi.org/10.1155/2016/8163803
10 https://doi.org/10.1164/rccm.200312-1651oc
11 schema:datePublished 2019-12
12 schema:datePublishedReg 2019-12-01
13 schema:description Background: Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term side effects with conventional treatment options can be a significant clinical problem. Recently, novel therapeutic approaches focus on targeting skewed immune responses providing a more effective, and less harmful approach. Among them, variable success has been reported using Omalizumab, when used in combination with classic therapies. This report describes an interesting case of severe adult onset difficult-to-treat atopic dermatitis dramatically improved in response to treatment with Omalizumab. Case presentation: We present a case of an adult male with severe allergic atopic dermatitis, with concomitant involvement of the face, neckline, trunk and forearms and systemic symptoms such as diarrhoea with important decrease of his daily quality of life. The patient had been prescribed oral steroids in addition to anti-histamines to no avail. Due to lack of response to classic therapies, strict diet, as well as to treatment with intravenous corticosteroids, an off-label treatment with Omalizumab based on patient weight and total IgE value was proposed. Clear clinical results were observed after only a few weeks with regards to systemic symptoms, and just after 2 months of treatment in regards to skin involvement. Conclusions: In the majority of treated patients the clinical improvement of cutaneous manifestations is expected after several months of treatment, as skin manifestations are the consequence of a chronic inflammatory process. The outstanding rapid response observed in this case as well as the persistence of the clinical remission suggests that the block of the IgE pathways modulate functions of cells involved in the pathogenic mechanisms of chronic skin inflammation but also in the acute phases observed in the flare-ups of the disease.
14 schema:genre research_article
15 schema:inLanguage en
16 schema:isAccessibleForFree true
17 schema:isPartOf N7ca0c7ea4db74f90b4d3de69ca3b1fb5
18 Nbcd2479a930f41b7a8af711ee0d6e906
19 sg:journal.1031275
20 schema:name Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
21 schema:pagination 5
22 schema:productId N01f59c77b70c40d8b923d427c6c3eefa
23 N3365faa949eb48e1bb83dc15be1dfb08
24 N3f43f77591174ad487e567dce85b5b1b
25 N946686dc5cc3419ebf0ae1885282799c
26 Nddf7d631ba454694b0ba1c8dc8278431
27 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112689654
28 https://doi.org/10.1186/s12948-019-0109-z
29 schema:sdDatePublished 2019-04-11T13:51
30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
31 schema:sdPublisher Nc0b2bba1244c4bcbac705c776e4cdce3
32 schema:url https://link.springer.com/10.1186%2Fs12948-019-0109-z
33 sgo:license sg:explorer/license/
34 sgo:sdDataset articles
35 rdf:type schema:ScholarlyArticle
36 N01f59c77b70c40d8b923d427c6c3eefa schema:name pubmed_id
37 schema:value 30911288
38 rdf:type schema:PropertyValue
39 N32a692dd74ed49cd893f2e09df2e0155 schema:affiliation https://www.grid.ac/institutes/grid.24704.35
40 schema:familyName Bormioli
41 schema:givenName Susanna
42 rdf:type schema:Person
43 N3365faa949eb48e1bb83dc15be1dfb08 schema:name nlm_unique_id
44 schema:value 101152195
45 rdf:type schema:PropertyValue
46 N35d5284bd4e64e3493fe33270753c320 schema:affiliation https://www.grid.ac/institutes/grid.24704.35
47 schema:familyName Vultaggio
48 schema:givenName Alessandra
49 rdf:type schema:Person
50 N3f43f77591174ad487e567dce85b5b1b schema:name doi
51 schema:value 10.1186/s12948-019-0109-z
52 rdf:type schema:PropertyValue
53 N46af941a1e184a40a91f9aa8dc1a49db rdf:first Naa4e046a9e1a4c5a8bd92df519597a71
54 rdf:rest N4cbbb32b5876449b9873e3092aca9604
55 N4b86f33d0dfa40489c214b4a2a032d45 schema:affiliation https://www.grid.ac/institutes/grid.24704.35
56 schema:familyName Nencini
57 schema:givenName Francesca
58 rdf:type schema:Person
59 N4cbbb32b5876449b9873e3092aca9604 rdf:first N35d5284bd4e64e3493fe33270753c320
60 rdf:rest rdf:nil
61 N60aa0cbd8ef146008d5e57899290bc5b rdf:first N32a692dd74ed49cd893f2e09df2e0155
62 rdf:rest Nd48ce610180d46d78086f228cae8066d
63 N65fc325f700143d5a0efbe4a32ba1540 rdf:first N4b86f33d0dfa40489c214b4a2a032d45
64 rdf:rest Nd2e7cf89765843b98ed7ec01a0ebfa7b
65 N7ca0c7ea4db74f90b4d3de69ca3b1fb5 schema:volumeNumber 17
66 rdf:type schema:PublicationVolume
67 N825c82a3d8704eed99d970cda38cb503 schema:affiliation https://www.grid.ac/institutes/grid.24704.35
68 schema:familyName Dies
69 schema:givenName Laura
70 rdf:type schema:Person
71 N946686dc5cc3419ebf0ae1885282799c schema:name dimensions_id
72 schema:value pub.1112689654
73 rdf:type schema:PropertyValue
74 Na2a977031d954180b9d39a2bc2106b2f schema:affiliation https://www.grid.ac/institutes/grid.24704.35
75 schema:familyName Grosso
76 schema:givenName Francesca
77 rdf:type schema:Person
78 Naa4e046a9e1a4c5a8bd92df519597a71 schema:affiliation https://www.grid.ac/institutes/grid.24704.35
79 schema:familyName Maggi
80 schema:givenName Enrico
81 rdf:type schema:Person
82 Nbcd2479a930f41b7a8af711ee0d6e906 schema:issueNumber 1
83 rdf:type schema:PublicationIssue
84 Nc0b2bba1244c4bcbac705c776e4cdce3 schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 Ncfe469062a3249b684642bd57f696f67 schema:affiliation https://www.grid.ac/institutes/grid.24704.35
87 schema:familyName Matucci
88 schema:givenName Andrea
89 rdf:type schema:Person
90 Nd2e7cf89765843b98ed7ec01a0ebfa7b rdf:first Na2a977031d954180b9d39a2bc2106b2f
91 rdf:rest N46af941a1e184a40a91f9aa8dc1a49db
92 Nd48ce610180d46d78086f228cae8066d rdf:first Ncfe469062a3249b684642bd57f696f67
93 rdf:rest Nfb2027d86ddf4df99f4d291ed7c45229
94 Nddf7d631ba454694b0ba1c8dc8278431 schema:name readcube_id
95 schema:value 2ae1ea4f610a2588750ff24aef603a48a8b8859a146070bed6b1ad5378d4cf9d
96 rdf:type schema:PropertyValue
97 Nfb2027d86ddf4df99f4d291ed7c45229 rdf:first N825c82a3d8704eed99d970cda38cb503
98 rdf:rest N65fc325f700143d5a0efbe4a32ba1540
99 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
100 schema:name Medical and Health Sciences
101 rdf:type schema:DefinedTerm
102 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
103 schema:name Clinical Sciences
104 rdf:type schema:DefinedTerm
105 sg:journal.1031275 schema:issn 1476-7961
106 schema:name Clinical and Molecular Allergy
107 rdf:type schema:Periodical
108 sg:pub.10.1186/s41232-017-0044-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085865564
109 https://doi.org/10.1186/s41232-017-0044-7
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1016/j.jaci.2009.10.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033887469
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1016/j.jaci.2016.05.038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048996340
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1016/s0140-6736(15)00149-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003359813
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1111/all.13083 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015924470
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1155/2016/8163803 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053444706
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1164/rccm.200312-1651oc schema:sameAs https://app.dimensions.ai/details/publication/pub.1037944429
122 rdf:type schema:CreativeWork
123 https://www.grid.ac/institutes/grid.24704.35 schema:alternateName Azienda Ospedaliero-Universitaria Careggi
124 schema:name Immunoallergology Unit, Department of Biomedicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
125 Immunology and Cellular Therapy, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy
126 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...